DUBLIN – Sanofi SA and Evotec AG formally completed their previously disclosed deal, under which the latter firm will take on a raft of early stage anti-infective programs from the big pharma firm. Hamburg-based Evotec is getting $60 million up front plus a commitment for continued funding from Paris-based Sanofi, which will retain option rights on each of the programs. Responsibility for a Sanofi research unit in Lyon, which employs 100 scientists, will transfer to the German firm, more than doubling its footprint in anti-infectives research.